Patterson Companies, Inc. PDCO reported adjusted earnings per share (EPS) of 37 cents in the fourth quarter of fiscal 2019, which missed the Zacks Consensus Estimate by 7.5%. However, the bottom line improved 23.3% year over year.
Net sales in the quarter were $1.44 billion, up 2.6% year over year, beating the Zacks Consensus Estimate by 0.6%.
FY19 at a Glance
Full-year adjusted earnings per share of $1.40 deteriorated 16.7% from $1.68 a year ago. The reported figure missed the Zacks Consensus Estimate of $1.43.
Revenues in fiscal 2019 grossed $5.57 billion, up 2% from the year-ago period. This figure met the Zacks Consensus Estimate.
Patterson Companies, Inc. Price, Consensus and EPS Surprise
Patterson Companies, Inc. price-consensus-eps-surprise-chart | Patterson Companies, Inc. Quote
The company currently distributes products through subsidiaries Patterson Dental and Patterson Animal Health.
This segment provides a complete range of consumable dental products, equipment, software, turnkey digital solutions and value-added services to dentists as well as laboratories throughout North America.
In the fourth quarter, dental sales rose 3.2% year over year to approximately $563.5 million.
Sales in the sub-segment totaled $312.1 million, down 1.9% year over year.
Dental Equipment & Software
Sales in the segment increased 11.9% on a year-over-year basis to $174.6 million.
This segment comprises technical service, parts and labor, software support services and office supplies. Sales at the segment improved 7% on a year-over-year basis to $76.8 million.
Animal Health Segment
This segment is a leading distributor of veterinary supplies to clinics, public and private institutions and shelters across the United States.
Coming to the fourth-quarter performance of the platform, sales increased 2.2% on a year-over-year basis to $866.4 million.
Sales at the segment were $6.8 million, dipped 0.7% from the year-ago quarter’s $6.9 million.
Gross Margin Analysis
Gross profit in the reported quarter was $312.5 million, up 7.8% year over year. As a percentage of revenues, gross margin of 21.8%, up 110 bps year over year.
Operating expenses in the reported quarter totaled $265.9 million, up nearly 7% on a year-over-year basis.
Fiscal 2020 Guidance
For fiscal 2020, Patterson Companies expects adjusted earnings per share in the range of $1.33 to $1.43. The mid-point of the guidance of $1.38 lies noticeably below the Zacks Consensus Estimate of $1.53.
Patterson Companies ended the fourth quarter of fiscal 2019 on a mixed note. We are upbeat about the Animal Health segment’s solid performance of late. In fact, the Dental unit witnessed a year-over-year upside in the quarter as well. The company provides a wide range of consumable supplies, equipment, software and value-added services.
A broad spectrum of products cushions the company against economic downturns in the MedTech space. We believe that a diverse product portfolio, strong veterinary business prospects, accretive acquisitions and strategic partnerships are key catalysts.
Meanwhile, declining Dental Consumable revenues remains a concern. Increase in operating expenses add to woes.
Patterson Companies has a Zacks Rank #3 (Hold).
Earnings of MedTech Majors at a Glance
Some better-ranked stocks which reported solid results this earning season are Baxter International Inc. BAX, DENTSPLY SIRONA Inc. XRAY and CONMED Corporation CNMD, each carrying a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
Baxter (BAX) reported first-quarter 2019 adjusted earnings of 76 cents per share, which surpassed the Zacks Consensus Estimate of 68 cents by 11.8%. Revenues of $2.63 billion outpaced the Zacks Consensus Estimate of $2.62 billion.
DENTSPLY reported adjusted earnings per share (EPS) of 49 cents in the first quarter of 2019, beating the Zacks Consensus Estimate of 38 cents. Revenues of $946.2 million surpassed the Zacks Consensus Estimate of $917.1 million.
CONMED posted first-quarter 2019 adjusted earnings per share of 57 cents, which beat the Zacks Consensus Estimate of 54 cents. Revenues were $218.4 million, surpassing the Zacks Consensus Estimate of $213 million.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119%and +164%in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Baxter International Inc. (BAX) : Free Stock Analysis Report
CONMED Corporation (CNMD) : Free Stock Analysis Report
DENTSPLY SIRONA Inc. (XRAY) : Free Stock Analysis Report
Patterson Companies, Inc. (PDCO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research